Enhanced Crenolanib-Based Therapies for FLT3 Mutated Proliferative Disorders

The present invention relates to novel improvements and enhancements of crenolanib-based therapies for treating FLT3 mutated proliferative disorders, providing more effective, efficient, and safe treatment options for patients.

The original patent, 'Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment,' has limitations in terms of dosing, efficacy, and patient monitoring. The new inventive concept addresses these limitations by introducing systems, methods, and compositions that enhance the treatment outcomes and patient experience.

The new inventive concept encompasses a system for treating FLT3 mutated proliferative disorders, comprising a crenolanib administration module and a monitoring module for tracking FLT3 tyrosine kinase activity. The system adjusts the crenolanib administration based on the FLT3 tyrosine kinase activity, ensuring optimal treatment outcomes. Additionally, the inventive concept includes methods for enhancing the efficacy of crenolanib, compositions for treating FLT3 mutated proliferative disorders, and systems for monitoring and treating these disorders. These improvements provide more targeted, efficient, and safe treatment options for patients.

The new claims introduce novel and non-obvious improvements to the original patent, including the integration of FLT3 tyrosine kinase activity monitoring, co-administration of second pharmaceutical agents, and the use of FLT3-binding antibodies. These advancements provide a significant inventive step over the prior art, enabling more effective and efficient treatment of FLT3 mutated proliferative disorders.

Alternative embodiments of the inventive concept may include varying the dose and administration schedule of crenolanib, using different types of FLT3 inhibitors or antibodies, or incorporating additional monitoring modules for tracking patient response. These variations ensure broad conceptual coverage and adaptability to different treatment scenarios.

The enhanced crenolanib-based therapies have significant commercial potential in the pharmaceutical industry, particularly in the treatment of FLT3 mutated proliferative disorders. The target market includes patients with relapsed or refractory FLT3 mutated cancers, as well as healthcare providers and researchers seeking more effective and efficient treatment options.